ABCL Q1 2025 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-57.5% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$63M-1479.6% margin

Net Income

-$46M-1077.2% margin

EPS (Diluted)

$-0.15

QoQ Revenue Growth

-16.1%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$22M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$321M

Stockholders' Equity

$1.0B

Cash & Equivalents

$159M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$10M	-57.5%
Gross Profit	$4M	$10M	-57.5%
Operating Income	-$63M	-$55M	-14.1%
Net Income	-$46M	-$41M	-12.3%

Revenue Segments

Research Fees

$4M96%

License

$167,0004%